CLINICAL TRIALS PROFILE FOR VARDENAFIL HYDROCHLORIDE

505(b)(2) Clinical Trials for VARDENAFIL HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT00631969 ↗	Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction	Completed	GlaxoSmithKline	Phase 3	2008-04-01	This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile dysfunction. After a 4-week unmedicated phase, patients will receive Vardenafil ODT or matching placebo for 12 weeks. Safety will be determined by laboratory and other evaluations. Efficacy will be determined by the results of different questionnaires and the patient diary that will be used.
New Dosage	NCT00631969 ↗	Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction	Completed	Schering-Plough	Phase 3	2008-04-01	This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile dysfunction. After a 4-week unmedicated phase, patients will receive Vardenafil ODT or matching placebo for 12 weeks. Safety will be determined by laboratory and other evaluations. Efficacy will be determined by the results of different questionnaires and the patient diary that will be used.
New Dosage	NCT00631969 ↗	Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction	Completed	Bayer	Phase 3	2008-04-01	This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile dysfunction. After a 4-week unmedicated phase, patients will receive Vardenafil ODT or matching placebo for 12 weeks. Safety will be determined by laboratory and other evaluations. Efficacy will be determined by the results of different questionnaires and the patient diary that will be used.
New Dosage	NCT00655629 ↗	Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.	Completed	GlaxoSmithKline	Phase 3	2008-04-01	This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile dysfunction. After a 4-week unmedicated phase, patients will receive Vardenafil ODT or matching placebo for 12 weeks. Safety will be determined by laboratory and other evaluations. Efficacy will be determined by the results of different questionnaires and the patient diary that will be used.
New Dosage	NCT00655629 ↗	Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.	Completed	Schering-Plough	Phase 3	2008-04-01	This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile dysfunction. After a 4-week unmedicated phase, patients will receive Vardenafil ODT or matching placebo for 12 weeks. Safety will be determined by laboratory and other evaluations. Efficacy will be determined by the results of different questionnaires and the patient diary that will be used.

All Clinical Trials for VARDENAFIL HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00377793 ↗	Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II	Completed	Bayer	Phase 4	2006-07-01	This trial is to provide additional important information on the impact of the treatment of the man its ED with vardenafil on partnership. This study is being run at up to 50 study centers in Europe and South Africa to evaluate the use of vardenafil in adult men with erectile dysfunction (often called impotence), and their female partner's sexual quality of life. Many men experience occasional erectile problems during their lives. However, when this becomes a continued problem, it can affect both the man and his female partner. The causes of erectile dysfunction are varied and may be due to physiological or emotional reasons. This study is designed to 1) study the effectiveness and safety of vardenafil, and 2) show whether treating a man its erectile dysfunction with vardenafil will improve his female partner its sexual quality of life. The second part (week 12) of the study (Educational program) a subgroup of subjects/couples, approximately 50% of the randomized subjects, will receive an educational program concerning ED in the from of a DVD.
NCT00379756 ↗	A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia	Completed	GlaxoSmithKline	Phase 4	2006-05-22	This is a study consisting of four periods (screening, run-in, treatment, follow-up). A four-week treatment-free, run-in period where the subject will make at least four attempts at intercourse on four separate days with at least 50% of the attempts must be unsuccessful. During run-in the subjects will be using a stopwatch to measure the time from erection perceived hard enough for penetration until withdrawal from the partner's vagina. Next there are 12 weeks of treatment with either placebo or LEVITRA. Each subject will be required to visit the clinic on 5 occasions over a period of 4 months.
NCT00448123 ↗	The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients	Completed	William Beaumont Hospitals	N/A	2007-02-01	To determine if emergency department patients with acute ureteral colic pain due to a ureteral stone who are treated with tamsulosin, versus placebo, will experience a shorter time to passage of their stone or resolution of their pain. A secondary study objective will be to determine if there is a relationship between response to tamsulosin and stone size or position in the ureter.
NCT00448123 ↗	The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients	Completed	Robert Swor	N/A	2007-02-01	To determine if emergency department patients with acute ureteral colic pain due to a ureteral stone who are treated with tamsulosin, versus placebo, will experience a shorter time to passage of their stone or resolution of their pain. A secondary study objective will be to determine if there is a relationship between response to tamsulosin and stone size or position in the ureter.
NCT00461123 ↗	Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy	Completed	Bayer	Phase 2	2007-03-01	The greenlight laser has an absorption maximum which is exactly the same as for hemoglobin. In the presence of hemoglobin, its application causes vaporization of the tissue and this effect depends on the concentration of hemoglobin in the respective tissue. Therefore, increase of blood-flow in the tissue (here: prostate gland) should exert better efficacy of the laser application and consequently shortening of the required duration of laser application.

Clinical Trial Conditions for VARDENAFIL HYDROCHLORIDE

Condition Name

Condition Name for VARDENAFIL HYDROCHLORIDE
Intervention	Trials
Erectile Dysfunction	54
Sexual Dysfunction	3
Pulmonary Arterial Hypertension	2
Overactive Bladder	2

Condition MeSH

Condition MeSH for VARDENAFIL HYDROCHLORIDE
Intervention	Trials
Erectile Dysfunction	59
Hypertension	6
Spinal Cord Injuries	4
Ischemia	4

Clinical Trial Locations for VARDENAFIL HYDROCHLORIDE

Trials by Country

Trials by Country for VARDENAFIL HYDROCHLORIDE
Location	Trials
United States	186
Germany	94
Spain	36
United Kingdom	32
Canada	29

Trials by US State

Trials by US State for VARDENAFIL HYDROCHLORIDE
Location	Trials
New York	12
Florida	12
California	12
North Carolina	10
New Jersey	8

Clinical Trial Progress for VARDENAFIL HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for VARDENAFIL HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE3	2
PHASE1	1
Phase 4	29

Clinical Trial Status

Clinical Trial Status for VARDENAFIL HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	67
Unknown status	9
Terminated	5

Clinical Trial Sponsors for VARDENAFIL HYDROCHLORIDE

Sponsor Name

Sponsor Name for VARDENAFIL HYDROCHLORIDE
Sponsor	Trials
Bayer	50
GlaxoSmithKline	19
Medical University of Vienna	2

Sponsor Type

Sponsor Type for VARDENAFIL HYDROCHLORIDE
Sponsor	Trials
Industry	86
Other	29
NIH	1

Vardenafil Hydrochloride: Clinical Trials, Market Analysis, and Projections

Last updated: February 19, 2026

Vardenafil hydrochloride is a phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). This report analyzes its current clinical trial landscape, assesses its market position, and projects future trends.

What is the Current Status of Vardenafil Hydrochloride Clinical Trials?

Vardenafil hydrochloride's primary regulatory approvals are for the treatment of erectile dysfunction. As of the latest available data, no new Phase I, II, or III clinical trials for novel indications or significant new formulations of vardenafil hydrochloride are actively recruiting or recently completed. The majority of ongoing research focuses on post-market surveillance, comparative effectiveness studies against other PDE5 inhibitors, or investigations into specific patient populations with ED.

• Indications: Erectile Dysfunction (ED).
• Active Trials: Limited new drug development trials. Focus is on comparative studies and observational research.
• Recruitment Status: Primarily closed for new drug development.
• Geographic Distribution: Trials are global, with significant participation in North America, Europe, and Asia.

A review of clinical trial registries indicates a historical pipeline for vardenafil hydrochloride that has largely matured. The focus has shifted from initial efficacy and safety profiling to exploring its use in combination therapies or understanding its long-term effects in diverse patient cohorts.

How Does Vardenafil Hydrochloride Perform in the Erectile Dysfunction Market?

Vardenafil hydrochloride, marketed under brand names such as Levitra and Staxyn, operates within a competitive market dominated by other PDE5 inhibitors, primarily sildenafil (Viagra) and tadalafil (Cialis). Its market share is influenced by factors including physician prescription patterns, patient preference, cost, and generic availability.

The market for ED treatments is substantial and has seen steady growth driven by increasing awareness, aging populations, and a greater willingness to seek treatment.

Key Market Dynamics:

• Market Size: The global market for ED treatments was valued at approximately USD 6.4 billion in 2022 [1]. Projections indicate a compound annual growth rate (CAGR) of 5.6% from 2023 to 2030, reaching an estimated USD 10.6 billion by 2030 [1].
• Competitive Landscape:
  • Sildenafil (Viagra): Holds the largest market share due to early market entry and strong brand recognition.
  • Tadalafil (Cialis): Offers longer duration of action and is also approved for benign prostatic hyperplasia (BPH), expanding its market reach.
  • Vardenafil (Levitra, Staxyn): Positioned as an alternative with a generally faster onset of action compared to tadalafil and comparable to sildenafil.
  • Avanafil (Stendra): A newer entrant with a favorable safety profile and rapid onset.
• Generic Competition: The availability of generic vardenafil has increased pricing pressure and expanded access, but also fragmented market share. Brand loyalty for established products remains a factor.
• Patient Factors:
  • Onset of Action: Vardenafil typically works within 25-60 minutes [2].
  • Duration of Action: Approximately 4-5 hours [2].
  • Food Interaction: Less affected by food compared to sildenafil, offering greater dosing flexibility.
• Pricing: Generic vardenafil hydrochloride is significantly more affordable than branded versions, impacting prescription choices. Average wholesale prices for generic formulations can range from $1 to $5 per dose, compared to branded prices that can exceed $30 per dose.
• Prescriber Behavior: Physicians consider efficacy, safety profile, contraindications (especially with nitrates), and patient-specific factors when prescribing.

The market for vardenafil hydrochloride is mature, with its growth largely driven by the overall expansion of the ED treatment market and the influx of generic alternatives. It occupies a significant, though not dominant, position among the available PDE5 inhibitors.

What is the Market Projection for Vardenafil Hydrochloride?

The market projection for vardenafil hydrochloride is intrinsically linked to the broader ED treatment market. While new patent-protected innovations are unlikely for vardenafil itself, its generic forms will continue to contribute to market volume and revenue.

Projected Market Trends:

1. Sustained Demand for PDE5 Inhibitors: The underlying demand for ED treatments is expected to grow. Vardenafil hydrochloride, as a widely available and effective generic option, will benefit from this trend.
2. Price Sensitivity: The prevalence of generic vardenafil will maintain price sensitivity in the market. This makes it an attractive option for healthcare systems and patients seeking cost-effective treatments.
3. Competition from New Entrants and Modalities: While PDE5 inhibitors remain the first-line therapy, the development of new treatment modalities, including vacuum erection devices, injectable therapies, and potentially novel pharmacological agents, could influence the long-term market share of existing oral medications. However, the convenience and efficacy of oral PDE5 inhibitors are likely to sustain their dominance in the near to medium term.
4. Focus on Patient Education and Access: Increased awareness campaigns and efforts to improve access to healthcare professionals and affordable medications will further drive demand.
5. Geographic Expansion: Emerging markets with increasing disposable income and a growing understanding of men's health issues will present opportunities for generic vardenafil sales.
6. Comparative Effectiveness Research: Ongoing research comparing vardenafil to other PDE5 inhibitors may highlight specific patient profiles or clinical scenarios where it offers superior outcomes, potentially influencing prescribing patterns.

Quantitative Projections:

• Overall ED Market Growth: As noted, the global ED market is projected to grow at a CAGR of 5.6% from 2023 to 2030 [1].
• Vardenafil Hydrochloride's Share: While specific market share projections for vardenafil hydrochloride are not independently published due to its generic status, its share is expected to remain stable within the PDE5 inhibitor segment. It will likely continue to capture a portion of the market driven by its cost-effectiveness and established efficacy profile. Assuming its current market share within the PDE5 inhibitor segment remains relatively constant, its absolute sales volume will increase in line with the overall market growth.
• Impact of Generics: Generic vardenafil hydrochloride will continue to be the primary driver of its market presence, offering an affordable alternative to branded ED medications.

The future market for vardenafil hydrochloride is characterized by stable demand within a growing overall ED market, driven primarily by its generic availability and cost-effectiveness. Its position is secured by its proven efficacy and favorable dosing characteristics, though it faces sustained competition from other PDE5 inhibitors and emerging treatment modalities.

Key Takeaways

• Vardenafil hydrochloride clinical development is largely concluded for its primary indication of ED. Current research focuses on comparative studies and post-market surveillance.
• The global erectile dysfunction market is valued at approximately USD 6.4 billion and is projected to grow to USD 10.6 billion by 2030, with a CAGR of 5.6%.
• Vardenafil hydrochloride competes with sildenafil and tadalafil, holding a stable market position due to its cost-effectiveness and favorable dosing.
• Generic availability is a key driver for vardenafil hydrochloride's market presence, offering an affordable treatment option.
• Market projections indicate sustained demand for vardenafil hydrochloride, benefiting from the overall growth of the ED market and its generic accessibility.

Frequently Asked Questions

1. Are there any new indications for vardenafil hydrochloride in clinical development? No new significant indications for vardenafil hydrochloride are currently in active development in major clinical trial phases.
2. What is the primary driver of vardenafil hydrochloride's market position? The primary driver is its availability as a cost-effective generic medication, coupled with its established efficacy and a favorable dosing profile for treating erectile dysfunction.
3. How does vardenafil hydrochloride compare in onset and duration of action to other PDE5 inhibitors? Vardenafil hydrochloride typically has an onset of action within 25-60 minutes and a duration of action of approximately 4-5 hours, placing it comparably to sildenafil and generally faster in onset but shorter in duration than tadalafil.
4. What is the projected growth rate for the overall erectile dysfunction market? The global erectile dysfunction market is projected to grow at a CAGR of 5.6% from 2023 to 2030.
5. Will new branded formulations of vardenafil hydrochloride likely emerge? Given the maturity of the drug and the market, the emergence of new branded formulations is unlikely; the market will continue to be dominated by generic versions and competition from other PDE5 inhibitors.

Citations

[1] Grand View Research. (2023). Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Drug Class (PDE5 Inhibitors, Testosterone, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023 – 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/erectile-dysfunction-drugs-market

[2] UpToDate. (n.d.). Patient information: Erectile dysfunction. Retrieved from https://www.uptodate.com/contents/erectile-dysfunction-beyond-the-basics